Syncor International (SCOR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Syncor International (SCOR)

SCOR 6.900

+1.2%

Dec 23 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: K.Martin who wrote (25)	2/6/1997 1:02:00 PM
From: Doug Prager	of 48

Several recent studies have validated the cost effectiveness of PET scanning primarily through the elimination of the need for much more expensive surgical procedures, particularly in the area of oncology. Moreover, the cost for imaging with FDG (the primary metabolic tracer used in PET and produced by Syncor's cyclotron facilities) will decline significantly with the up and coming availability of gamma cameras dually configured for coincidence detection capability as well as standard single photon imaging. The regional availability of FDG through Syncor's radiopharmacies will also markedly decrease the cost of these procedures as individual institutions will no longer have the large captial expenditure required for an on-site cyclotron and high operating expense to produce the radiopharmaceuticals.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next